Trends in the Cumulative Post-Marketing Reporting Rates of Retinal Vasculitis and/or Retinal Vascular Occlusion and Associated Vision Loss with Brolucizumab
Crossref DOI link: https://doi.org/10.1007/s40123-022-00617-5
Published Online: 2022-12-05
Published Print: 2023-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Igwe, Franklin
Lodha, Amit
Ravindran, Arun
Text and Data Mining valid from 2022-12-05
Version of Record valid from 2022-12-05
Article History
Received: 24 October 2022
Accepted: 14 November 2022
First Online: 5 December 2022